Global Recombinant Human Coagulation VIIa Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Coagulation VIIa Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
Recombinant Human Coagulation VIIa report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Coagulation VIIa market is projected to reach US$ 1467.3 million in 2034, increasing from US$ 1133.8 million in 2022, with the CAGR of 3.7% during the period of 2024 to 2034. Demand from Congenital Hemophilia and Acquired Hemophilia are the major drivers for the industry.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Coagulation VIIa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Congenital Hemophilia
Acquired Hemophilia
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Coagulation VIIa market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Human Coagulation VIIa, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Human Coagulation VIIa industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Human Coagulation VIIa in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Human Coagulation VIIa introduction, etc. Recombinant Human Coagulation VIIa Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Human Coagulation VIIa market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Recombinant Human Coagulation VIIa report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Coagulation VIIa market is projected to reach US$ 1467.3 million in 2034, increasing from US$ 1133.8 million in 2022, with the CAGR of 3.7% during the period of 2024 to 2034. Demand from Congenital Hemophilia and Acquired Hemophilia are the major drivers for the industry.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Coagulation VIIa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Coagulation VIIa market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Human Coagulation VIIa, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Human Coagulation VIIa industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Human Coagulation VIIa in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Human Coagulation VIIa introduction, etc. Recombinant Human Coagulation VIIa Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Human Coagulation VIIa market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices